Filing Details
- Accession Number:
- 0001127602-23-027292
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-13 20:30:14
- Reporting Period:
- 2023-11-08
- Accepted Time:
- 2023-11-13 20:30:14
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 318154 | Amgen Inc | AMGN | Biological Products, (No Disgnostic Substances) (2836) | 953540776 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1365306 | P Jonathan Graham | One Amgen Center Drive Thousand Oaks CA 91320-1799 | Evp, Gen. Counsel & Secy. | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-11-08 | 10,000 | $272.81 | 28,078 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The price reported is an average price. The prices ranged from $272.79 to $272.96 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,122 RSUs which will vest on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments each of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- These shares include 579 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Billionaire Hedge Funds
